128-62-1
Chemical Structure
Noscapine
Synonym(s): (S,R)-Noscapine
- CAS No.: 128-62-1
- Formula:C22H23NO7
- Molecular Weight:413.42
IUPAC Name: (S)-6,7-dimethoxy-3-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3H)-one
InChIKey: AKNNEGZIBPJZJG-MSOLQXFVSA-N
SMILES: O=C1O[C@H]([C@@H]2N(C)CCC3=C2C(OC)=C(OCO4)C4=C3)C5=C1C(OC)=C(OC)C=C5
Biological Activity: Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Noscapine | 99.98% | Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Noscapine (Standard) | ≥98% | Noscapine (Standard) is the analytical standard of Noscapine. This product is intended for research and analytical applications. Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Noscapine-13C,d3 | 96.79% | Noscapine-13C,d3 is a 13C- labeled and deuterated labeled Noscapine. Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.99
HY-13716ANoscapine hydrochloride -
Similarity Score 0.88
HY-W746289Narcotoline -
Similarity Score 0.78
HY-B0927Hydrastine -
Similarity Score 0.72
HY-118425(+)-Adlumine -
Similarity Score 0.72
HY-N0942(-)-Corlumine -
Similarity Score 0.71
HY-170778Tubulin polymerization-IN-77 -
Similarity Score 0.70
HY-172915p53 Stabilizer 2 -
Similarity Score 0.67
HY-U00065Tritoqualine -
Similarity Score 0.65
HY-N0219RBicuculline (Standard) -
Explore the MedChemAI to find more analogs
References
- [1]. Jaren W Landen, et al. Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth. Clin Cancer Res. 2004 Aug 1;10(15):5187-201. [Content Brief]
- [2]. Yunfan Yang, et al. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. Theranostics. 2015 Mar 2;5(7):656-66. [Content Brief]
- [3]. Vartika Tomar, et al. Noscapine and Its Analogs as Chemotherapeutic Agent: Current Updates. Curr Top Med Chem. 2017;17(2):174-188. [Content Brief]
- [4]. Bianca Lokhorst, et al. Interaction of OTC Drug Noscapine and Acenocoumarol and Phenprocoumon. Br J Clin Pharmacol. 2019 May;85(5):1041-1043. [Content Brief]
- [5]. S A Ebrahimi, et al. Interaction of Noscapine With the Bradykinin Mediation of the Cough Response. Acta Physiol Hung. 2003;90(2):147-55. [Content Brief]
